[go: up one dir, main page]

HK1206248A1 - 他汀類藥物和ω-3脂肪酸的組合物 - Google Patents

他汀類藥物和ω-3脂肪酸的組合物 Download PDF

Info

Publication number
HK1206248A1
HK1206248A1 HK15106807.3A HK15106807A HK1206248A1 HK 1206248 A1 HK1206248 A1 HK 1206248A1 HK 15106807 A HK15106807 A HK 15106807A HK 1206248 A1 HK1206248 A1 HK 1206248A1
Authority
HK
Hong Kong
Prior art keywords
statins
compositions
fatty acids
omega
pufas
Prior art date
Application number
HK15106807.3A
Other languages
English (en)
Inventor
Bernardus Nicolaas MACHIELSE
Timothy J. Maines
Michael H. Davidson
Bharat M. Mehta
Original Assignee
Omthera Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omthera Pharmaceuticals Inc. filed Critical Omthera Pharmaceuticals Inc.
Publication of HK1206248A1 publication Critical patent/HK1206248A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK15106807.3A 2012-05-07 2013-05-07 他汀類藥物和ω-3脂肪酸的組合物 HK1206248A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643764P 2012-05-07 2012-05-07
US201261643764P 2012-05-07
PCT/US2013/039972 WO2013169797A1 (en) 2012-05-07 2013-05-07 Compositions of statins and omega-3 fatty acids

Publications (1)

Publication Number Publication Date
HK1206248A1 true HK1206248A1 (zh) 2016-01-08

Family

ID=49512692

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106807.3A HK1206248A1 (zh) 2012-05-07 2013-05-07 他汀類藥物和ω-3脂肪酸的組合物

Country Status (10)

Country Link
US (2) US9492545B2 (zh)
EP (1) EP2846779A4 (zh)
JP (1) JP6173437B2 (zh)
KR (1) KR20150028233A (zh)
CN (1) CN104661654A (zh)
AR (1) AR095182A1 (zh)
HK (1) HK1206248A1 (zh)
RU (1) RU2645075C2 (zh)
TW (1) TW201347754A (zh)
WO (1) WO2013169797A1 (zh)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2334295T3 (pl) 2008-09-02 2017-12-29 Amarin Pharmaceuticals Ltd Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania
CN104856985B (zh) 2009-04-29 2019-01-04 阿马里纳制药爱尔兰有限公司 稳定的药物组合物和使用其的方法
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CA3026006C (en) 2009-06-15 2021-09-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
WO2011038122A1 (en) 2009-09-23 2011-03-31 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US20140127289A1 (en) 2010-11-29 2014-05-08 Armarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
JP6307442B2 (ja) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
PE20142459A1 (es) 2012-01-06 2015-01-23 Omthera Pharmaceuticals Inc Composiciones enriquecidas con dpa de acidos grasos omega 3 poliinsaturados en forma de acido libre
KR20150028233A (ko) * 2012-05-07 2015-03-13 옴테라 파마슈티칼스, 인크. 스타틴 및 오메가-３ 지방산의 조성물
RS67161B1 (sr) 2012-06-29 2025-09-30 Amarin Pharmaceuticals Ie Ltd Etil estar eikozapentaenske kiseline za upotrebu u smanjenju rizika od nesmrtonosnog šloga kod pacijenta na terapiji statinima
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
CN106794149A (zh) * 2014-08-13 2017-05-31 韩国联合制药株式会社 含ω‑3脂肪酸酯和他汀类的口服给药复合制剂
AU2015307306B2 (en) 2014-08-28 2021-01-21 Newamsterdam Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors
WO2016069446A1 (en) * 2014-10-28 2016-05-06 Omthera Pharmaceuticals Inc Methods for modulating plasma levels of lipoproteins
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
MX388141B (es) * 2015-04-01 2025-03-19 Pronova Biopharma Norge As EL USO DE DERIVADOS DE ÁCIDOS GRASOS POLINSATURADOS PARA REDUCIR apoC-III.
JP7341916B2 (ja) * 2015-04-01 2023-09-11 ビーエーエスエフ エーエス アポｃ３を低下させるためのチアオキソ化合物の使用
KR102644400B1 (ko) 2015-04-28 2024-03-06 바스프 에이에스 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
US10966937B2 (en) * 2015-05-04 2021-04-06 Cytometix, Inc. Compositions and methods for delivery of polyunsaturated fatty acid derivatives and analogs
WO2017023165A1 (en) 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator
WO2017023166A1 (en) 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and a cholesterol absorption inhibitor
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
HRP20241643T1 (hr) 2017-12-06 2025-02-14 Basf As Derivati masnih kiselina za liječenje nealkoholnog steatohepatitisa
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
CA3227153A1 (en) 2021-07-26 2023-02-02 Newamsterdam Pharma B.V. Treatment of his hyporesponders

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2033745B (en) 1978-05-26 1983-08-17 Wellcome Found Fatty acid and derivatives thereof for use in treatment or prophylaxis of thromboembolic conditions
JPS5735512A (en) 1980-06-27 1982-02-26 Nippon Oil & Fats Co Ltd Preventive and remedy for thrombosis
US4377526A (en) 1981-05-15 1983-03-22 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid and its esters
BR8803255A (pt) 1981-11-10 1990-02-06 Century Lab Inc Processo de extracao e purificacao de acidos graxos poli-insaturados de fontes naturais
JPS59157018A (ja) 1983-02-27 1984-09-06 Furointo Sangyo Kk 新規なる被覆含油カプセル剤形
EP0347509A1 (en) 1988-06-21 1989-12-27 Century Laboratories Inc. A process of extraction and purification of polyunsaturated fatty acids from natural sources
CH669208A5 (fr) 1986-12-17 1989-02-28 Nestle Sa Procede de fractionnement en continu d'un melange d'acides gras.
US5243046A (en) 1986-12-17 1993-09-07 Nestec S.A. Process for the continuous fractionation of a mixture of fatty acids
EP0289204B1 (en) 1987-04-27 1991-07-17 Efamol Holdings Plc Lithium salt-containing pharmaceutical compositions
US4843095A (en) 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
ZA885473B (en) 1987-08-07 1989-03-29 Century Lab Inc Free fatty acids for treatment of diabetes mellitus
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
CA2151820C (en) 1993-01-15 2000-11-28 Stephen Joseph Demichele Structured lipids
US5767156A (en) 1993-10-06 1998-06-16 Peptide Technology Limited Polyunsaturated fatty acids and uses thereof
US5494684A (en) 1994-02-23 1996-02-27 Bar-Ilan University Plant protection from infection by Phytophthora infestans using fish oil
GB9404483D0 (en) 1994-03-08 1994-04-20 Norsk Hydro As Refining marine oil compositions
ES2131129T3 (es) 1994-05-09 1999-07-16 Nestle Sa Procedimiento para la preparacion de un concentrado de esteres de acidos grasos poliinsaturados.
GB9509764D0 (en) 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
GB2300807B (en) 1995-05-15 1999-08-18 Tillotts Pharma Ag Oral dosage forms of omega-3 polynunsaturated acids for the treatment of inflammatory bowel disease
WO1997039759A2 (en) 1996-04-24 1997-10-30 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
PT843972E (pt) 1996-11-20 2002-12-31 Nutricia Nv Composicao nutritiva que inclui gorduras para o tratamento do sindrome metabolico
AU6184298A (en) 1997-02-25 1998-09-09 Genzyme Transgenics Corporation Transgenically produced non-secreted proteins
US6852870B2 (en) 1999-03-22 2005-02-08 Andrew Stoll Omega-3 fatty acids in the treatment of depression
WO1999029316A1 (en) * 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
NO312973B1 (no) 1999-02-17 2002-07-22 Norsk Hydro As Lipase-katalysert forestring av marine oljer
US7112609B2 (en) 1999-06-01 2006-09-26 Drugtech Corporation Nutritional supplements
JP2001054396A (ja) 1999-06-08 2001-02-27 Nippon Suisan Kaisha Ltd リパーゼによる高度不飽和脂肪酸含有油脂の製造方法
WO2001006983A2 (en) 1999-07-22 2001-02-01 Incell Corporation, Llc Fatty acids to minimize cancer therapy side effects
NO310113B1 (no) 1999-08-11 2001-05-21 Norsk Hydro As Fremgangsmåte for utvinning av flerumettede fettsyrer fra ureakomplekser
EP1211955A1 (en) 1999-08-30 2002-06-12 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
EP1106072B1 (en) 1999-12-10 2005-11-30 Loders Croklaan B.V. Palmitoleic acid and its use in foods
AU2634101A (en) 2000-01-06 2001-07-16 Martek Biosciences Corporation Therapeutic preparations of highly unsaturated fatty acids
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
GB0016452D0 (en) 2000-07-04 2000-08-23 Kilgowan Limited Vitamin K and essential fatty acids
EP1178103A1 (en) 2000-08-02 2002-02-06 Dsm N.V. Purifying crude pufa oils
KR20010008387A (ko) 2000-11-30 2001-02-05 이성권 결정화방법을 이용한 고순도 불포화지방산의 분리 정제 방법
US20040241249A1 (en) 2001-06-18 2004-12-02 Tina Sampalis Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport
GB2385852A (en) 2002-02-27 2003-09-03 Rothamsted Ex Station Delta 6-desaturases from Primulaceae
AU2003218319A1 (en) 2002-03-22 2003-10-13 Doc's Guide, Inc. Multivitamin and mineral nutritional supplement
DE10214005A1 (de) 2002-03-27 2003-10-09 Volker Bartz Blutfettsenker zur oralen Einnahme, bestehend aus einem Gemisch aus den Omega-3-Fettsäuren EPA (Eicosapentaensäure) und DHA (Docosapentaensäure) und Pektin und/oder Guar als wirksame Substanzen, sowie gegebenenfalls zusätzlichen Stoffen wie antioxidative Vitamine, Aminosäuren und Spurenelemente
ITMI20020731A1 (it) 2002-04-08 2003-10-08 Ibsa Inst Biochimique Sa Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3
NZ518504A (en) 2002-04-22 2005-05-27 Ind Res Ltd Use of near-critical fluids in the separation of saturated and mono-unsaturated fatty acids from urea-containing solutions
NO319194B1 (no) 2002-11-14 2005-06-27 Pronova Biocare As Lipase-katalysert forestringsfremgangsmate av marine oljer
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
AU2003288606A1 (en) 2002-12-20 2004-07-14 Pronova Biocare As Use of a fatty acid composition for treatment of male infertility
WO2004098311A1 (en) 2003-05-05 2004-11-18 Denofa As Fish oils with an altered fatty acid profile, method of producing same and their use
US6846942B2 (en) 2003-05-20 2005-01-25 David Rubin Method for preparing pure EPA and pure DHA
US7759507B2 (en) 2003-09-05 2010-07-20 Abbott Laboratories Lipid system and methods of use
ITMI20032247A1 (it) 2003-11-19 2005-05-20 Tiberio Bruzzese Interazione di derivati polari di composti insaturi con substrati inorganici
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
GB0403247D0 (en) * 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US20050267197A1 (en) 2004-05-25 2005-12-01 Roger Berlin Compositions containing policosanol and HMG-Co-A reductase inhibitor and their pharmaceutical uses
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413729D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
US20070265341A1 (en) 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
WO2006004438A1 (en) 2004-07-05 2006-01-12 Otago Innovation Limited Hoki fish liver oil, fractions thereof and therapeutic uses
CA2576196A1 (en) 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
WO2007130714A1 (en) 2006-02-01 2007-11-15 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
WO2007130713A1 (en) 2006-02-01 2007-11-15 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
US20090042979A1 (en) 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
WO2006036967A1 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Solubilizing a drug for use in a coating
ES2255426B1 (es) 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
US20070191467A1 (en) 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
JP2008522970A (ja) 2004-12-06 2008-07-03 レリアント ファーマスーティカルズ インコーポレイテッド 脂質療法用のオメガ−３脂肪酸類及び異常脂質血症薬剤
DE102004062141A1 (de) 2004-12-23 2006-07-06 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Verfahren zur Herstellung eines Rohöls aus Gemischen von Mikroorganismen und Pflanzen, das so hergestellte Öl sowie die spezifischen Verwendungen des so hergestellten und gegebenenfalls zusätzlich raffinierten Öls
EP1845999A4 (en) 2005-01-24 2010-09-22 Pronova Biocare As USE OF A DHA-CONTAINING FATTY ACID COMPOSITION FOR THE PRODUCTION OF A PHARMACEUTICAL OR FOOD PRODUCT FOR THE TREATMENT OF AMYLOSIS RELATED DISEASES
EP1858352B1 (en) 2005-02-18 2013-06-05 Delante Health AS A composition comprising a powder containing microencapsulated polyunsaturated long-chain esterified fatty acids distributed in an effervescent base
EP1861087A4 (en) * 2005-03-08 2010-02-10 Reliant Pharmaceuticals Inc TREATMENT WITH STATINE AND OMEGA-3-FATTY ACID AS A COMBINATION PRODUCT THEREOF
DE102005013779A1 (de) 2005-03-22 2006-09-28 Basf Plant Science Gmbh Verfahren zur Herstellung von mehrfach ungesättigten C20- und C22-Fettsäuren mit mindestens vier Doppelbindungen in transgenen Pflanzen
WO2006102896A2 (en) 2005-03-29 2006-10-05 Aalborg Universitet A process to concentrate ω3-pufa from fish oil by selective hydrolysis using cutinase immobilized on zeolite nay
KR100539357B1 (ko) 2005-04-11 2005-12-28 동부한농화학 주식회사 불포화 지방산의 제조방법
WO2006117664A1 (en) 2005-05-04 2006-11-09 Pronova Biopharma Norge As New dha derivatives and their use as medicaments
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
EP2630869B1 (en) 2005-07-01 2016-12-14 DSM IP Assets B.V. Polyunsaturated fatty acid-containing oil product and uses and production thereof
US20070020340A1 (en) 2005-07-25 2007-01-25 David Rubin Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension
ITMI20051560A1 (it) 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
US7356120B2 (en) 2005-09-23 2008-04-08 Accuray Incorporated Integrated quality assurance for in image guided radiation treatment delivery system
FR2896172B1 (fr) 2006-01-17 2008-10-10 Polaris Soc Par Actions Simpli Nouveau procede de stabilisation des acides gras polyinsatures et les compositions ainsi obtenus.
DE102006008030A1 (de) 2006-02-21 2007-08-23 Basf Plant Science Gmbh Verfahren zur Herstellung von mehrfach ungesättigten Fettsäuren
AR059376A1 (es) 2006-02-21 2008-03-26 Basf Plant Science Gmbh Procedimiento para la produccion de acidos grasos poliinsaturados
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
WO2007128801A1 (en) 2006-05-08 2007-11-15 Novartis Ag Combination of organic compounds
US20100310650A1 (en) 2006-06-26 2010-12-09 Roberto Valducci Pharmaceutical composition for the oral administration of omega polyenoic fatty acids and one or more active principles incompatible therewith, and a process for its preparation
US8003813B2 (en) 2006-06-27 2011-08-23 Pos Pilot Plant Corporation Process for separating saturated and unsaturated fatty acids
KR100684641B1 (ko) 2006-07-25 2007-02-22 주식회사 일신웰스 유지 조성물, 이를 함유하는 식품 및 건강보조식품
EP2124905B1 (en) 2007-01-10 2016-09-07 DSM Nutritional Products AG Microcapsules including pea protein
JP2010515773A (ja) 2007-01-16 2010-05-13 リライアント・ファーマシューティカルズ・インコーポレイテッド 非ステロイド系抗炎症薬およびオメガ−３脂肪酸を用いる治療ならびにその組合せ生成物
US20110190389A1 (en) 2007-02-20 2011-08-04 Linda Arterburn Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
WO2008113177A1 (en) 2007-03-20 2008-09-25 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
CA2685272A1 (en) 2007-04-26 2008-11-06 Patrick Adlercreutz A polyunsaturated fatty acid (pufa) enriched marine oil comprising eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), and a process of production thereof
US20080299187A1 (en) 2007-06-01 2008-12-04 Joar Opheim Substances for Reducing Occurence of Major Cardiac Events in Humans
US20100119600A1 (en) 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
US20090011012A1 (en) 2007-07-06 2009-01-08 Baum Seth J Fatty acid compositions and methods of use
CL2008002020A1 (es) 2007-07-12 2008-11-14 Ocean Nutrition Canada Ltd Metodo de modificacion de un aceite, que comprende hidrolizar gliceridos con una solucion de lipasa thermomyces lanuginosus, separar la fraccion de acido graso saturado de la fraccion de glicerido hidrolizado y esterificar los gliceridos hidrolizados en la presencia de candida antarctica lipasa b; y composicion de aceite.
CA2694054C (en) 2007-07-25 2015-11-17 Epax As Omega-3 fatty acid fortified composition
US9556401B2 (en) 2007-07-30 2017-01-31 Nippon Suisan Kaisha, Ltd. Method for producing EPA-enriched oil and DHA-enriched oil
WO2009020406A1 (en) 2007-08-07 2009-02-12 Granate Seed Limited Methods of making lipid substances, lipid substances made thereby and uses thereof
WO2009028457A1 (ja) 2007-08-29 2009-03-05 Shinshu University 非アルコール性脂肪肝炎治療薬
ITMI20072142A1 (it) 2007-11-08 2009-05-09 Yervant Zarmanian Composizioni farmaceutiche contenenti statine e derivati di acidi grassi omega-3
DE102007055344A1 (de) 2007-11-19 2009-05-20 K. D. Pharma Bexbach Gmbh Neue Verwendung von Omega-3-Fettsäure(n)
EP2229939A4 (en) 2008-01-10 2011-04-27 Takeda Pharmaceutical CAPSULE FORMULATION
US20090182049A1 (en) 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
JP2011522913A (ja) 2008-05-15 2011-08-04 プロノヴァ バイオファーマ ノルゲ アーエス オキアミ油加工方法
PL2334295T3 (pl) 2008-09-02 2017-12-29 Amarin Pharmaceuticals Ltd Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania
US20100062057A1 (en) 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
PT2337857T (pt) 2008-10-02 2017-06-02 Gonzalez Ramon Nieves Resumo
GB0818472D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
PL2349250T3 (pl) 2008-10-31 2017-09-29 Lipid Pharmaceuticals Ehf. Kwasy Tłuszczowe Do Stosowania Jako Lek
ITFI20080243A1 (it) 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.
SI2596786T1 (sl) 2009-02-10 2020-03-31 Amarin Pharmaceuticals Ireland Limited, Uporaba etilestra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije
WO2010119319A1 (en) 2009-03-09 2010-10-21 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
MX2011010821A (es) 2009-04-17 2012-01-20 Cela Vista Pharmaceuticals Ltd Composiciones ricas en acidos grasos omega-3 con bajo contenido en acido fitanico.
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN104856985B (zh) 2009-04-29 2019-01-04 阿马里纳制药爱尔兰有限公司 稳定的药物组合物和使用其的方法
CA3026006C (en) 2009-06-15 2021-09-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US8304551B2 (en) 2009-09-01 2012-11-06 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
WO2011038122A1 (en) 2009-09-23 2011-03-31 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
CN102724972A (zh) 2009-10-23 2012-10-10 普罗诺瓦生物医药挪威公司 脂肪酸油混合物的包衣胶囊和包衣片剂
SG181446A1 (en) 2009-12-23 2012-07-30 Defiante Farmaceutica Sa Combination composition useful for treating cardiovascular diseases
WO2011095284A1 (de) 2010-02-02 2011-08-11 Cognis Ip Management Gmbh Anreicherung von mehrfach ungesättigten fettsäuren
GB201006204D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
AU2011242843A1 (en) 2010-04-22 2012-09-27 E. I. Du Pont De Nemours And Company Method for obtaining polyunsaturated fatty acid-containing compositions from microbial biomass
CA2803477C (en) 2010-06-25 2019-04-30 Epax As Process for separating polyunsaturated fatty acids from long chain unsaturated or less saturated fatty acids
EP2613767A4 (en) 2010-09-08 2014-03-19 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a free fatty acid, and a statin
JP2013537185A (ja) * 2010-09-08 2013-09-30 プロノヴァ・バイオファーマ・ノルゲ・アーエス 遊離酸の形のｅｐａおよびｄｈａを含む脂肪酸油混合物と界面活性剤とスタチンとを含む組成物
CN103221524B (zh) 2010-09-24 2021-01-01 普罗诺瓦生物医药挪威公司 用于浓缩omega-3脂肪酸的方法
WO2012087153A1 (en) 2010-12-23 2012-06-28 Marine Bioproducts As Enrichment of marine oils with omega-3 polyunsaturated fatty acids by lipase-catalysed hydrolysis
EP2476425B1 (en) 2011-01-14 2014-03-19 Visiotact Pharma Composition comprising OPC and Omega-3 for preventing and/or inhibiting the development of diabetic retinopathy
CA2826506C (en) 2011-02-04 2017-07-25 Biocopea Limited Compositions and methods for treating chronic inflammation and inflammatory diseases
JP2014505729A (ja) 2011-02-16 2014-03-06 ピヴォタル セラピューティクス インコーポレイテッド コレステロールの低減および心血管事象の低減のための、コレステロール吸収阻害剤（アゼチジノン）およびω３脂肪酸（ＥＰＡ、ＤＨＡ、ＤＰＡ）
JP2014505731A (ja) 2011-02-16 2014-03-06 ピヴォタル セラピューティクス インコーポレイテッド 心血管疾患のリスク因子を治療するための、ＥＰＡ、ＤＨＡおよびＤＰＡを含むω３製剤
WO2012112520A1 (en) 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. A formulations comprising omega 3 fatty acids and an anti obesity agent for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics
WO2012112517A1 (en) 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd)
CA2827585A1 (en) 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
WO2012112902A1 (en) 2011-02-18 2012-08-23 Martek Biosciences Corporation Methods of preparing free polyunsaturated fatty acids
US20140051877A1 (en) 2011-04-28 2014-02-20 Nandakishore Jeevanrao Duragkar Eicosapentaenoic acid (epa) as polyunsaturated free fatty acid in its directly compressible powder form and process of isolation thereof
CN102311868B (zh) 2011-04-29 2017-05-24 塞拉斯有限责任公司 一种无溶剂提取富含磷脂和中性油脂的磷虾油的方法
US8697676B2 (en) 2011-06-15 2014-04-15 Ronald E Rosedale Omega-3 fatty acid nutriceutical composition and optimization method
US20130095179A1 (en) 2011-09-15 2013-04-18 Omthera Pharmaceuticals, Inc. Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy
US20140316003A1 (en) 2011-10-21 2014-10-23 Omthera Pharmaceuticals, Inc. Methods and compositions for treating or preventing attention deficit hyperactivity disorder
PE20142459A1 (es) * 2012-01-06 2015-01-23 Omthera Pharmaceuticals Inc Composiciones enriquecidas con dpa de acidos grasos omega 3 poliinsaturados en forma de acido libre
KR20150028233A (ko) * 2012-05-07 2015-03-13 옴테라 파마슈티칼스, 인크. 스타틴 및 오메가-３ 지방산의 조성물
CA2916208A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
US20140194512A1 (en) 2012-06-17 2014-07-10 Matinas Biopharma, Inc. Compositions comprising docosapentaenoic acid and methods of use

Also Published As

Publication number Publication date
JP6173437B2 (ja) 2017-08-02
AR095182A1 (es) 2015-09-30
KR20150028233A (ko) 2015-03-13
EP2846779A1 (en) 2015-03-18
TW201347754A (zh) 2013-12-01
US20150104504A1 (en) 2015-04-16
CN104661654A (zh) 2015-05-27
JP2015520150A (ja) 2015-07-16
RU2014146111A (ru) 2016-06-27
US9492545B2 (en) 2016-11-15
EP2846779A4 (en) 2015-12-16
RU2645075C2 (ru) 2018-02-15
US20130295173A1 (en) 2013-11-07
WO2013169797A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
HK1206248A1 (zh) 他汀類藥物和ω-3脂肪酸的組合物
MY165048A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
EA201400152A1 (ru) Микроорганизмы, продуцирующие эйкозапентаеновую кислоту, композиции, содержащие жирные кислоты, и способы их получения и применения
MX2016004487A (es) Capsulas blandas de capa entérica que constan de ácidos grasos poli insaturados.
WO2014074552A3 (en) Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
MX2022010507A (es) Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
MX372724B (es) Formulaciones de acido eicosapentaenoico (epa).
PH12016501194B1 (en) Lipid comprising long chain polyunsaturated fatty acids
ZA201405956B (en) Method for the preparation of triglycerides of medium-chain length fatty acids.
MX2012005744A (es) Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
WO2012013331A3 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases
IL230500B (en) Eicosapentaenoic acid-producing microorganisms, fatty acid compositions and methods of making and uses thereof
HK1209286A1 (zh) 从油组合物去除不期望的组分
GEP201606568B (en) Compositions for the treatment of neurologic disorders
PH12018500035A1 (en) Nutritional compositions and methods for promoting cognitive development
PH12018500036A1 (en) Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
WO2016040570A3 (en) Dietary emulsion formulations and methods for using the same
WO2014165190A3 (en) Compositions comprising docosapentaenoic acid and methods of use
WO2012171001A3 (en) Food products containing beta-glucans and omega-3 fatty acids
WO2014089511A3 (en) Administering compositions comprising docosapentaenoic acid
HK1244218A1 (zh) 包括多不饱和游离脂肪酸的毫米胶囊配制品
EA201692398A1 (ru) Гомогенная композиция для перорального введения, содержащая омега-3 полиненасыщенные жирные кислоты и ресвератрол
GB201209344D0 (en) Omega-6 enriched pufa phospholipids
EP4327870A3 (en) Method for improving white matter integrity in hyperphenylalaninemia and phenylketonuria patients
MX2015005235A (es) Metodo para reducir trigliceridos.